We continue our focus on investing in biotech with Eden Rahim, Portfolio Manager and Options Strategist, Next Edge Capital. While acknowledging the risks involved in biotech, Rahim says the sector is recovering with "considerable room to run." He also says "a genomic/gene-editing revolution is underway in biotech that is transforming drug development."